BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: González-juanatey JR, Mostaza JM, Lobos JM, Abarca B, Llisterri JL, Baron-esquivias G, Galve E, Lidón RM, Garcia-moll FX, Sánchez PL, Suárez C, Millán J, Pallares V, Alemán JJ, Egocheaga I. Documento de consenso del uso clínico de la Polypill en la prevención secundaria del riesgo cardiovascular. Medicina Clínica 2017;148:139.e1-139.e15. [DOI: 10.1016/j.medcli.2016.10.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Singh K, Crossan C, Laba T, Roy A, Hayes A, Salam A, Jan S, Lord J, Tandon N, Rodgers A, Patel A, Thom S, Prabhakaran D. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. International Journal of Cardiology 2018;262:71-8. [DOI: 10.1016/j.ijcard.2018.03.082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Nansseu JR, Tankeu AT, Kamtchum-tatuene J, Noubiap JJ. Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges. J Clin Hypertens 2018;20:168-73. [DOI: 10.1111/jch.13162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gutiérrez-Valencia M, Martínez-Velilla N. Applicability of fixed-dose combination therapy in complex patients. Med Clin (Barc) 2017;149:367. [PMID: 28476450 DOI: 10.1016/j.medcli.2017.03.022] [Reference Citation Analysis]